Literature DB >> 10373073

Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection.

C Thiede1, M Florek, M Bornhäuser, M Ritter, B Mohr, C Brendel, G Ehninger, A Neubauer.   

Abstract

Monitoring the engraftment of donor cells after allogeneic blood stem cell transplantation (BSCT) may be important for the early diagnosis of graft failure or relapse of disease. Several techniques have been reported for this purpose. PCR-based assays analyzing polymorphic short tandem repeat (STR) markers are attractive because they are sensitive and can be performed rapidly. The intent of the present study was to test a novel approach for the quantification of mixed chimerism using a commercial multiplex STR assay with fluorescence-based detection for forensic purposes. The feasibility of this assay and the accuracy of quantitative results was tested using serial cell mixtures of unrelated individuals. Sample preparation was optimized to obtain information from minute amounts of starting material, eg from patients with aplasia or from sorted cell populations. Using the STR-PCR, discrimination between donor and recipient was possible in all patients analyzed (n = 25). Cell dilution experiments showed a linear correlation between the cell numbers added and the proportions found, with the limit of detection for a minor cell population being 5%. Comparison of values obtained with standard FISH analysis in patients transplanted from sex-mismatched donors showed an excellent correlation with the STR-PCR results. Taken together, this procedure allows the rapid, versatile and accurate quantification of mixed chimerism, even with minuscule numbers of cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373073     DOI: 10.1038/sj.bmt.1701779

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  39 in total

1.  Feasibility of a cost-effective approach to evaluate short tandem repeat markers suitable for chimerism follow-up.

Authors:  Ariela F Fundia; Carlos De Brasi; Irene Larripa
Journal:  Mol Diagn       Date:  2004

Review 2.  Hematologic aspects of myeloablative therapy and bone marrow transplantation.

Authors:  Roger S Riley; Michael Idowu; Alden Chesney; Shawn Zhao; John McCarty; Lawrence S Lamb; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

3.  Tri-allelic patterns at the D7S820 locus detected in two generations of a Chinese family.

Authors:  Erlie Jiang; Jie Pan; Mingzhe Han; Liang Chen; Qiaoling Ma; Jialin Wei; Yong Huang; Sizhou Feng; Qin Sun; Peili Xiao; Zhongzheng Zheng
Journal:  Int J Legal Med       Date:  2015-03-25       Impact factor: 2.686

4.  Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

Authors:  A P Nair; P Walker; A Kalff; K Bergin; J Hocking; S Avery; D J Curtis; S Patil; T Das; D Klarica; S Morgan; J Muirhead; M Gorniak; J Reynolds; A Spencer
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

5.  Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.

Authors:  Martin Bornhäuser; Uta Oelschlaegel; Uwe Platzbecker; Gesine Bug; Karin Lutterbeck; Michael G Kiehl; Johannes Schetelig; Alexander Kiani; Thomas Illmer; Markus Schaich; Catrin Theuser; Brigitte Mohr; Cornelia Brendel; Axel A Fauser; Stefan Klein; Hans Martin; Gerhard Ehninger; Christian Thiede
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

6.  No recovery of T-cell receptor excision circles (TRECs) after non-myeloablative allogeneic hematopoietic stem cell transplantation is correlated with the onset of GvHD.

Authors:  Grzegorz K Przybylski; Karl-A Kreuzer; Wolfgang Siegert; Christian A Schmidt
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

7.  Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection.

Authors:  Marija Debeljak; Evelina Mocci; Max C Morrison; Aparna Pallavajjalla; Katie Beierl; Marie Amiel; Michaël Noë; Laura D Wood; Ming-Tseh Lin; Christopher D Gocke; Alison P Klein; Ephraim J Fuchs; Richard J Jones; James R Eshleman
Journal:  J Mol Diagn       Date:  2017-05       Impact factor: 5.568

8.  Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1).

Authors:  Gulbu Uzel; Emilia Tng; Sergio D Rosenzweig; Amy P Hsu; Jacqueline M Shaw; Mitchell E Horwitz; Gilda F Linton; Stacie M Anderson; Martha R Kirby; Jaõ B Oliveira; Margaret R Brown; Thomas A Fleisher; S K Alex Law; Steven M Holland
Journal:  Blood       Date:  2007-09-17       Impact factor: 22.113

9.  Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Authors:  Xavier Poiré; Andrew Artz; Richard A Larson; Justin Kline; Olatoyosi Odenike; Elizabeth Rich; Lucy Godley; Wendy Stock; Koen van Besien
Journal:  Leuk Lymphoma       Date:  2009-01

10.  Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.

Authors:  Ilseung Choi; Yasunobu Abe; Rie Ohtsuka; Takamitsu Matsushima; Yoshimichi Tachikawa; Eriko Nagasawa; Junji Nishimura; Shoichi Inaba; Hajime Nawata; Koichiro Muta
Journal:  Int J Hematol       Date:  2004-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.